Erritzoe D

UCL Centre for Consciousness Research, Department of Experimental Psychology, University College London, 26 Bedford Way, London WC1H 0AP, United Kingdom.

Erritzoe D

Neurite Complexity and Plasticity Markers Track Synaptic Vesicle Density in the Living Human Brain: A Multimodal PET-MRI-EEG Study

Micro-phenomenology of immersion and perceived presences under DMT.

Psilocybin therapy for adult females with anorexia nervosa: pilot study.

Divergent changes in perturbation-induced brain reconfiguration following depression treatment with psilocybin and escitalopram

Sex-Specific Effects of Psilocybin Versus Escitalopram on Anxiety and Anhedonia: A Bayesian Reanalysis of Antidepressant Treatment Outcomes

Distinct brain responses to psilocybin and escitalopram in depression captured by the Fluctuation-Dissipation Theorem

Human brain changes after first psilocybin use.

How to set up a psychedelic study: Unique considerations for research involving human participants.

Detecting neuroplastic effects induced by ketamine in healthy human subjects: A multimodal approach.

A short-acting psychedelic intervention for major depressive disorder: a phase IIa randomized placebo-controlled trial.

High hopes? Precision psychedelic addiction medicine.

Negative affective bias in depression following treatment with psilocybin or escitalopram - a secondary analysis from a randomized trial.

Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects.

A long, strange trip: Ketamine treatment in psychiatry.

Neural effects and phenomenology of nondual meditation and 5-MeO-DMT in an expert meditation practitioner

Neural effects and phenomenology of nondual meditation and 5-MeO-DMT in an expert meditation practitioner

Validation of the Imperial Psychedelic Predictor Scale - CORRIGENDUM.

Psychedelic Therapy, Positive Emotional Experiences, and the Central Role of Self-Compassion

Improved mental health outcomes and normalised spontaneous EEG activity in veterans reporting a history of traumatic brain injuries following participation in a psilocybin retreat.

Perturbing whole-brain models of brain hierarchy: An application for depression following pharmacological treatment.

Single-dose (10 mg) psilocybin reduces symptoms in adults with obsessive-compulsive disorder: A pharmacological challenge study.

Correction: Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial.

The Music for Subanesthetic Infusions of Ketamine randomised clinical trial: ketamine as a psychedelic treatment for highly refractory depression.

A model training curriculum for psychedelic, psycholytic, and entactogen-assisted psychotherapy.

Enhanced meaning in life following psychedelic use: converging evidence from controlled and naturalistic studies.

Serotonergic psychedelics for depression: A comprehensive overview.

Reduced Brain Responsiveness to Emotional Stimuli With Escitalopram But Not Psilocybin Therapy for Depression.

Detecting neuroplastic effects induced by ketamine in healthy human subjects: a multimodal approach

Dissociable effects of psilocybin and escitalopram for depression on processing of musical surprises.

Exploring 5-MeO-DMT as a pharmacological model for deconstructed consciousness.

Neuroplasticity and psychedelics: A comprehensive examination of classic and non-classic compounds in pre and clinical models.

The effects of psilocybin therapy versus escitalopram on cognitive bias: A secondary analysis of a randomized controlled trial

Psychedelics and Suicide-Related Outcomes: A Systematic Review.

Dissociable effects of LSD and MDMA on striato-cortical connectivity in healthy subjects

Study Protocol for 'PsilOCD: A Pharmacological Challenge Study Evaluating the Effects of the 5-HT2A Agonist Psilocybin on the Neurocognitive and Clinical Correlates of Compulsivity'.

From relaxed beliefs under psychedelics (REBUS) to revised beliefs after psychedelics (REBAS).

An investigation of acute physiological and psychological moderators of psychedelic-induced personality change among healthy volunteers.

Human brain changes after first psilocybin use

Neuroimaging and the Investigation of Drug-Drug Interactions Involving Psychedelics.

Impact of psilocybin on cognitive function: A systematic review.

Validation of the imperial psychedelic predictor scale.

Effect of psilocybin versus escitalopram on depression symptom severity in patients with moderate-to-severe major depressive disorder: observational 6-month follow-up of a phase 2, double-blind, randomised, controlled trial.

Longitudinal experiences of Canadians receiving compassionate access to psilocybin-assisted psychotherapy.

Interrupting the Psychedelic Experience Through Contextual Manipulation to Study Experience Efficacy.

Psychedelics in developmental stuttering to modulate brain functioning: a new therapeutic perspective?

Study protocol for "Psilocybin in patients with fibromyalgia: brain biomarkers of action".

Psychedelics and the 'inner healer': Myth or mechanism?

Effects of discontinuation of serotonergic antidepressants prior to psilocybin therapy versus escitalopram for major depression.

Psychiatric risks for worsened mental health after psychedelic use.

Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity.

Membrane Permeation of Psychedelic Tryptamines by Dynamic Simulations.

Effects of DMT on mental health outcomes in healthy volunteers.

Psychedelics and sexual functioning: a mixed-methods study.

Interactions between classic psychedelics and serotonergic antidepressants: Effects on the acute psychedelic subjective experience, well-being and depressive symptoms from a prospective survey study.

Assessing expectancy and suggestibility in a trial of escitalopram v. psilocybin for depression.

Safety, tolerability, pharmacodynamic and wellbeing effects of SPL026 (dimethyltryptamine fumarate) in healthy participants: a randomized, placebo-controlled phase 1 trial.

Psilocybin and Other Classic Psychedelics in Depression.

Knowledge gaps in psychedelic medicalisation: Preclinical and neuroimaging mechanisms.

Neuroimaging in psychedelic drug development: past, present, and future.

Case analysis of long-term negative psychological responses to psychedelics.

The Montreal model: an integrative biomedical-psychedelic approach to ketamine for severe treatment-resistant depression.

Co-use of MDMA with psilocybin/LSD may buffer against challenging experiences and enhance positive experiences.

The difference between 'placebo group' and 'placebo control': a case study in psychedelic microdosing.

Assessing the risk of symptom worsening in psilocybin-assisted therapy for depression: A systematic review and individual participant data meta-analysis.

Psychedelic therapy in the treatment of addiction: the past, present and future.

Prevalence and therapeutic impact of adverse life event reexperiencing under ceremonial ayahuasca.

Personality change in a trial of psilocybin therapy v. escitalopram treatment for depression.

Pharmacokinetics of N,N-dimethyltryptamine in Humans.

Psychological and physiological effects of extended DMT

Focusing on the negative: cases of long-term negative psychological responses to psychedelics

Human brain effects of DMT assessed via EEG-fMRI.

Body mass index (BMI) does not predict responses to psilocybin.

A Bayesian Reanalysis of a Trial of Psilocybin versus Escitalopram for Depression.

Evidence for tolerance in psychedelic microdosing from the self-blinding microdose trial

Effects of psilocybin versus escitalopram on rumination and thought suppression in depression.

Antidepressant effects of a psychedelic experience in a large prospective naturalistic sample.

Neuroimaging in psychedelic drug development: Past, present, and future

PHARMACOKINETICS OF N,N-DIMETHYLTRYPTAMINE FUMARATE IN HUMANS